

November 4, 2019

---

# **Emerald Bioscience to Present at Cowen 2nd Annual Boston Cannabis Conference**

LONG BEACH, CA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- [Emerald Bioscience, Inc.](#) (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will participate in a panel discussion at the Cowen 2nd Annual Boston Cannabis Conference, to be held November 12 -13, 2019, at the InterContinental Hotel in Boston, MA, with 1x1 investor meetings being held throughout the conference.

Details of the panel discussion are as follows:

**Panel:** Clinical Research in Cannabinoids

**Date and Time:** Tuesday, November 12, 2019 at 11:15 – 12:00 PM ET

**Location:** InterContinental Hotel, Boston, MA

## **About Emerald Bioscience, Inc.**

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Emerald Bioscience is part of the [Emerald Group](#), which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body's endocannabinoid system.

For more information, visit [www.emeraldbio.life](http://www.emeraldbio.life)

## **FORWARD LOOKING STATEMENTS**

This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock

price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.

#### CONTACT

Emerald Bioscience Investor Relations  
Emerald Health Sciences  
Karam Takhar  
Email: [ir@emeraldbio.life](mailto:ir@emeraldbio.life)  
Phone: 949-336-3437

Douglas Cesario  
Chief Financial Officer  
Email: [doug@emeraldbio.life](mailto:doug@emeraldbio.life)  
Phone: 949-336-3437



Source: Emerald Bioscience, Inc.